Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Adaptive Seamless Design, Randomized, Controlled Trial To Evaluate Safety And Immunogenicity of 2 Dose-Regimen of BBV87 Chikungunya Vaccine In Healthy Subjects Aged 12 to 65 Years in Latin America and Asia.

NCT04566484 is registered in ClinicalTrials.gov with International Vaccine Institute as lead sponsor.

NCT NCT04566484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04566484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Adaptive Seamless Design, Randomized, Controlled Trial To Evaluate Safety And Immunogenicity of 2 Dose-Regimen of BBV87 Chikungunya Vaccine In Healthy Subjects Aged 12 to 65 Years in Latin America and Asia.
Lead sponsor
International Vaccine Institute
Phase
Phase 2/3
Overall status
Terminated
Start date
August 1, 2021
Completion date
May 31, 2025
Enrollment
3,210 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

chikungunya